PUBLISHER: The Business Research Company | PRODUCT CODE: 1938615
PUBLISHER: The Business Research Company | PRODUCT CODE: 1938615
Animal biotechnology involves the application of science and engineering techniques to modify living organisms for the benefit of humans and other animals. This field utilizes genetic engineering to modify the genome of animals, with applications ranging from pharmaceuticals and industrial processes to agriculture.
The main products of animal biotechnology include diagnostics tests, vaccines, drugs, reproductive and genetic technologies, as well as feed additives for animals such as companion and livestock. Diagnostics tests are a set of techniques used to diagnose diseases or conditions in organisms. Animal biotechnology is applied in various areas, including the diagnosis and treatment of animal diseases, preventive care, drug development, and other applications. These products are utilized in laboratories, point-of-care testing (in-house testing), veterinary hospitals and clinics, and other end-use settings.
Tariffs have affected the animal biotechnology market by raising the cost of imported diagnostics, vaccines, drugs, and reproductive technologies, impacting laboratories and veterinary hospitals budgets. Companion and livestock segments in North America, Europe, and Asia-Pacific are most affected due to reliance on high-quality imported products. On the positive side, tariffs are encouraging local production, promoting innovation in cost-effective biotechnology solutions, and strengthening regional supply chains to reduce import dependency.
The animal biotechnology market research report is one of a series of new reports from The Business Research Company that provides animal biotechnology market statistics, including animal biotechnology industry global market size, regional shares, competitors with a animal biotechnology market share, detailed animal biotechnology market segments, market trends and opportunities, and any further data you may need to thrive in the animal biotechnology industry. This animal biotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The animal biotechnology market size has grown rapidly in recent years. It will grow from $32.89 billion in 2025 to $36.19 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to advancements in recombinant vaccine technology, increasing prevalence of animal diseases, growth of companion and livestock population, rising demand for animal-derived pharmaceuticals, expansion of veterinary diagnostic laboratories.
The animal biotechnology market size is expected to see rapid growth in the next few years. It will grow to $53.4 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to development of precision gene-editing tools, increasing focus on preventive veterinary care, growth of biopharmaceutical applications in animals, rising investments in animal reproductive technologies, adoption of AI and big data for animal health monitoring. Major trends in the forecast period include increasing adoption of genetic engineering in livestock, development of personalized veterinary therapies, growth in immunodiagnostic and molecular testing, expansion of artificial insemination and embryo transfer technologies, rising demand for nutraceuticals and feed additives.
The increasing awareness of animal health and welfare is anticipated to drive the growth of the animal biotechnology market in the future. Animal health and welfare encompass the interactions between people and animals and the responsibility to ensure that animals are treated properly and compassionately. Within this context, animal biotechnology plays a significant role in enhancing animal productivity by improving growth, reproductive quality, nutrition, feed efficiency, food safety, and other factors, leading to more effective resource utilization. For example, in May 2023, the Humane Society launched the "More Than a Pet" campaign to highlight the importance of equitable access to veterinary care, particularly for underserved communities. Through this initiative, over 14,800 pets received 64,000 services in 2023 via community outreach programs designed to enhance animal welfare in low-resource areas. The campaign emphasizes providing essential veterinary care and support to improve the well-being of animals in these underserved regions. Thus, the rising awareness of animal health and welfare is propelling the growth of the animal biotechnology market.
Major companies in the animal biotechnology sector are investing in innovative technological solutions, such as the development of the Animal Biotech Resource Page, to bolster their market position. This resource page serves as a comprehensive public library gathering animal biotechnology resources obtained from global workshops. For instance, the International Service for the Acquisition of Agri-biotech Applications (ISAAA), a non-profit organization based in the United States, launched the Animal Biotech Resource Page in June 2023. This platform offers a wide array of materials, including presentation slides, podcasts, videos, and workshop content, covering the latest advancements in the sector and pertinent regulatory strategies. These global forums facilitate discussions and consensus-building on various subjects. The primary objective of the Animal Biotech Resource Page is to provide researchers, regulators, students, and key stakeholders within the animal biotech field with ongoing opportunities for learning and discourse. By fostering a deeper understanding of the technology, this initiative aims to maximize its benefits for both the environment and society.
Zoetis Inc., a US-based pharmaceutical company, made a strategic move in September 2023 by acquiring Adivo, a biotechnology company headquartered in Germany, for an undisclosed amount. This acquisition grants Zoetis access to state-of-the-art species-specific antibody libraries and advanced technological expertise. The integration of Adivo's resources positions Zoetis to develop a wide range of cutting-edge veterinary treatments. With the new capabilities from Adivo, Zoetis aims to address unmet needs in companion animals, particularly in areas like cancer treatment, inflammatory disorders, and others. This strategic acquisition further strengthens Zoetis's position in delivering innovative therapeutic antibodies, catering to the evolving demands of its clientele within the veterinary field.
Major companies operating in the animal biotechnology market are Zoetis Inc., Boehringer Ingelheim International GmbH, Biogenesis Bago SA, Merck & Co Inc., Virbac, Elanco Animal Health Incorporated, Randox Laboratories Ltd., Santa Cruz Biotechnology Inc., IDEXX Laboratories Inc., IDVet, Heska Corporation, INDICAL BIOSCIENCE GmbH, BioChek BV, Ceva Sante Animale, Dalan Animal Health, Vetigenics, Vetoquinol S.A., Neogen Corporation, Abaxis Inc., Henry Schein Animal Health, Patterson Companies Inc., Covetrus Inc., Phibro Animal Health Corporation, Novartis Animal Health, Bayer AG, Bioniche Life Sciences Inc., Bio-Rad Laboratories Inc., Biovet JSC, Bovogen Biologicals Pty Ltd.
North America was the largest region in the animal biotechnology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal biotechnology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the animal biotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The animal biotechnology market includes revenues earned by entities by using animal biotechnology for dogs, cats, horses, poultry, swine, cattle, sheep, goats and fish. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Animal Biotechnology Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses animal biotechnology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for animal biotechnology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The animal biotechnology market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.